Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine brokerages that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $5.57.

Several research firms recently commented on MRSN. William Blair began coverage on Mersana Therapeutics in a research report on Thursday, February 6th. They set an "outperform" rating on the stock. Citigroup assumed coverage on shares of Mersana Therapeutics in a report on Friday, November 15th. They set a "buy" rating and a $5.00 price target on the stock. Finally, Wedbush reissued an "outperform" rating and set a $4.00 price objective (down from $7.00) on shares of Mersana Therapeutics in a report on Friday, January 10th.

Institutional Trading of Mersana Therapeutics

Large investors have recently added to or reduced their stakes in the business. US Bancorp DE purchased a new position in shares of Mersana Therapeutics during the 3rd quarter worth $31,000. Dynamic Technology Lab Private Ltd purchased a new position in Mersana Therapeutics during the third quarter valued at $34,000. China Universal Asset Management Co. Ltd. bought a new stake in Mersana Therapeutics during the fourth quarter valued at about $37,000. Intech Investment Management LLC purchased a new stake in Mersana Therapeutics in the third quarter worth about $52,000. Finally, Quarry LP bought a new position in shares of Mersana Therapeutics in the third quarter worth about $57,000. 93.92% of the stock is currently owned by institutional investors.

Mersana Therapeutics Stock Down 3.7 %

MRSN traded down $0.02 during trading on Friday, hitting $0.56. 3,367,053 shares of the company's stock traded hands, compared to its average volume of 7,855,180. Mersana Therapeutics has a 12-month low of $0.49 and a 12-month high of $6.28. The company's 50 day simple moving average is $1.08 and its two-hundred day simple moving average is $1.62. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35. The stock has a market capitalization of $69.30 million, a price-to-earnings ratio of -0.92 and a beta of 1.39.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.